---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-300537"
form_type: "8-K"
ticker: "MDXG"
cik: "0001376339"
company_name: "MIMEDX GROUP, INC."
filed_at: "2022-12-08T23:59:59+00:00"
generated_at: "2026-06-21T07:23:45.756265+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MiMedx licenses Turn's PermaFusion platform for $1M upfront, up to $9.55M in milestones for FleX AM product rights

## Summary
- MiMedx obtains exclusive worldwide license to Turn's PermaFusion antimicrobial platform for wound, burn, and surgical fields.
- Upfront cash payment of $1 million; potential milestone payments up to $9.55 million upon FDA 510(k) clearance of FleX AM product.
- MiMedx acquires commercial rights to FleX AM, a particulate bovine collagen powder with antimicrobial properties, expected FDA clearance in 2023.
- Turn will receive royalties on sales of products developed using the licensed technology.

## SEC filing metadata
- accession: 0001193125-22-300537
- form_type: 8-K
- ticker: MDXG
- cik: 0001376339
- company_name: MIMEDX GROUP, INC.
- filed_at: 2022-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1376339/000119312522300537/0001193125-22-300537-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1376339/000119312522300537/d396655d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-300537
- JSON: https://secwatch.observer/filing/0001193125-22-300537.json
- Plain text: https://secwatch.observer/filing/0001193125-22-300537.txt

## Key facts
- Material Agreements
  MIMEDX GROUP, INC. entered into Platform Intellectual Property License with Global Health Solutions, Inc. (d.b.a. Turn Therapeutics) valued at Upfront cash payment of $1 million; future payments up to $9.55 million contingent upon FDA 510(k) c (effective 2022-12-07).
  - Action: entry
  - Agreement: license
  - Counterparty: Global Health Solutions, Inc. (d.b.a. Turn Therapeutics)
  - Value: Upfront cash payment of $1 million; future payments up to $9.55 million contingent upon FDA 510(k) c
  - Effective: 2022-12-07
  source text: On December 7, 2022, MiMedx Group, Inc. (“MIMEDX” or the “Company”) entered into a Platform Intellectual Property License (the “License Agreement”) with Global Health Solutions, Inc. (d.b.a. Turn Therapeutics or “Turn”), providing MIMEDX an exclusive, worldwide sublicensable license to use Turn’s proprietary antimicrobial technology platform (PermaFusion®) to develop antimicrobial line extensions and new products.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1376339/000119312522300537/0001193125-22-300537-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.